Evogene Ltd. (EVGN) Stock Price, Financials & Summary

Price chart

Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3

Key dataNov 3, 2026

Open$0.36

From 52W high−71.44%

Volume22608.00

Market cap$5.69M

P/E (TTM)—

P/S (TTM)4.4x

Div yield—

Key dataNov 3, 2026

Open

$0.36

From 52W high

−71.44%

Volume

22608.00

Market cap

$5.69M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

42.3

MomentumView details →

1D Return

−0.30%

YTD Return

−66.23%

SummaryUpdated Jun 1, 2026

Evogene Ltd. (NASDAQ:EVGN) is an Israeli computational biology company founded in 1999 and headquartered in Rehovot, Israel. The company went public in 2010 and operates as a technology-driven life sciences platform that uses artificial intelligence and big data to discover and develop products across agriculture, human health, and industrial applications. Evogene has evolved from a traditional biotechnology company into a computational biology pioneer, leveraging its proprietary Computational Predictive Biology (CPB) platform to create multiple subsidiary companies targeting specific market segments.

Ask drillr about Evogene Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

5.7x

P/S (TTM)

4.4x

P/B (TTM)

−1.7x

ProfitabilityView details →

Gross Margin

−123.87%

Net Margin

−694.19%

EBITDA Margin

−961.36%

ROE (TTM)

275.78%

ROA (TTM)

−67.51%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

−80.43%

EPS YoY

+59.51%

FCF YoY

+36.55%

Revenue CAGR 3Y

+32.01%

EPS CAGR 3Y

+62.63%

EBITDA YoY

−67.71%

MomentumView details →

1D Return

−0.30%

YTD Return

−66.23%

1Y Return

−69.55%

RSI (14)

42.3

vs 50D SMA

−15.77%

vs 200D SMA

−43.46%

Capital & dividendView details →

Debt/Equity

−0.64x

Current Ratio

3.57x

Quick Ratio

3.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

51.85%

Beats (12Q)

5/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−56.05%

Rev Surprise

8.17%

Financials snapshotView financials →

Revenue (TTM)

1.31M

Net Income (TTM)

−9.07M

Op. CF (TTM)

−11.54M

Next earningsNov 19, 2026 →

Latest newsMore news →

Evogene announced acute graft-versus-host disease as the target indication for its internal AI-driven drug discovery program.7d ago

Nasdaq granted Evogene Ltd. an additional 180-day period to regain compliance with the minimum bid price requirement.35d ago

Similar companies

Longeveron Inc.LGVN Acurx Pharmaceuticals, Inc.ACXP Senti Biosciences, Inc.SNTI Processa Pharmaceuticals, Inc.PCSA Skye Bioscience, Inc.SKYE Instinct Bio Technical Co. Holdings Inc.BIOT Find similar companies →

Latest newsMore news →

Evogene announced acute graft-versus-host disease as the target indication for its internal AI-driven drug discovery program.7d ago Nasdaq granted Evogene Ltd. an additional 180-day period to regain compliance with the minimum bid price requirement.35d ago